Sanofi offers refunds for Cablivi in novel model for rebates
Pharmaceutical Technology
JANUARY 27, 2023
In 2019, Cablivi became the first FDA-approved , nanobody-based medicine for acquired thrombotic thrombocytopenic purpura (aTTP), an ultra-orphan condition that causes blood clots in small blood vessels around the body. However, it is consistent in regards that it simply seeks provider attestation opposed to actual documentation,” he added.
52 
Let's personalize your content